University of Pittsburgh - Of the Commonwealth System of Higher Education Patent applications |
Patent application number | Title | Published |
20160137692 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 05-19-2016 |
20160136407 | MICRONEEDLE ARRAYS FOR CANCER THERAPY APPLICATIONS - A method of forming a microneedle array can include forming a microneedle array having one or more chemotherapeutic agents. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more chemotherapeutic agents can be present in a higher concentration in the plurality of microneedles than in the base portion. | 05-19-2016 |
20160135917 | POWERING AND READING IMPLANTED DEVICES - A method of providing RF energy to a wireless transponder device includes outputting primary RF energy in a form wherein the primary RF energy comprises a plurality of RF bursts, with each consecutive pair of the RF bursts being separated by an associated time interval, and outputting secondary continuous wave RF energy in between each of the RF bursts of the primary RF energy during at least a portion of each of the associated time intervals. Also, a reader device implementing this method. | 05-19-2016 |
20160129155 | MUSCULOSKELETAL TISSUE FABRICATION - Described herein are methods of fabricating human cell-based engineered musculoskeletal tissues (hCEMTs) using three dimensional fabrication technology that involves injectable materials with in situ polymerization/solidification capability and/or solid free-form fabrication. Also described is the usage of hCEMTs for tissue repair and drug testing. | 05-12-2016 |
20160108104 | APOLIPOPROTEIN E POLYPEPTIDES AND THEIR USE - Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods | 04-21-2016 |
20160100755 | SIGNAL NORMALIZATION AMONG MULTIPLE OPTICAL COHERENCE TOMOGRAPHY DEVICES - The present disclosure is directed to systems and methods for normalizing an image of an eye among multiple optical coherence tomography (OCT) devices. The system can receive an OCT image and generate a normalized OCT image. The system is configured to normalize a sample density of the received image, normalize an amount of noise using a suitable noise reduction technique, normalize a distribution of signal amplitudes of the image, and then normalize a signal quality of the image. The resulting normalized image of the eye can then be used in the comparison among OCT images taken from multiple OCT devices. | 04-14-2016 |
20160090387 | CALCIUM CHANNEL AGONISTS - Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: | 03-31-2016 |
20160089414 | NOVEL INHIBITORS OF NOX1 - The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer. | 03-31-2016 |
20160083351 | TETRAHYDROISOQUINOLINES AS SELECTIVE NADPH OXIDASE 2 INHIBITORS - Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof: | 03-24-2016 |
20160076827 | VARIABLE THERMAL INSULATION - A device for selectively controlling the passage of thermal energy through the device from a first space to a second space by selectively varying an overall thermal conductivity of the device comprises a structure having at least one component movable from a first position to a second position and an actuator mechanically coupled to the component for moving the component from the first position to the second position. When the at least one component is positioned in the first position the device exhibits a first thermal conductivity and when the at least one component is positioned in the second position the device exhibits a second thermal conductivity different from the first thermal conductivity. | 03-17-2016 |
20160074521 | PEPTIDE-MEDIATED INTRAVESICAL DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS - The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells. | 03-17-2016 |
20160068556 | TARGETED NITROXIDE AGENTS - A compound having a structure of: | 03-10-2016 |
20160058794 | LYMPH NODE AS A SITE FOR TRANSPLANTATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES AND ORGANS - The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain. | 03-03-2016 |
20160052969 | TEMPLATES FOR CONTROLLING SYNTHESIS OF NANOPARTICLES INTO DISCRETE ASSEMBLIES - An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step. | 02-25-2016 |
20160051709 | COMPOSITION-CONTROLLED NOBLE METAL-TRANSITION METAL SMALL NANOPARTICLE ALLOYS WITH NIR-EMISSION AND HIGH T2 RELAXIVITY AND METHOD FOR MAKING SAME - A method for producing small nanoparticles of a discrete noble metal-transition metal nanoparticle alloy, comprising: mixing, at room temperature in air, a first aqueous solution having a first molar ratio of a noble metal and a transition metal with an organic ligand and a reducing agent. A method for producing small nanoparticles of a discrete gold-cobalt nanoparticle alloy, comprising: mixing, at room temperature in air, a first aqueous solution having a first molar ratio of HAuCl | 02-25-2016 |
20160045552 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY BOWEL DISEASE WITHOUT COLECTOMY - Methods and compositions for treating diseased or damaged tissue, such as Inflammatory Bowel Disease, e.g., Ulcerative Colitis, include tissue regeneration using stem cells or tissue grafts which stimulate stem cell migration to the damaged tissue. The tissue grafts can be extracellular matrix (ECM) material, such as tissue-specific extracellular matrix (TS-ECM). The methods can also include mucosal resection of the damaged or diseased tissue prior to placement of the graft. | 02-18-2016 |
20160045467 | NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES - Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ. | 02-18-2016 |
20160039910 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA - Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization. | 02-11-2016 |
20160038578 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF - Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 02-11-2016 |
20160022779 | ACTIVATORS OF CXCR3 FOR THE TREATMENT OF ANGIOPATHIES OF THE EYE - The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof. | 01-28-2016 |
20160020382 | OXIDE INTERFACE DISPLAYING ELECTRONICALLY CONTROLLABLE FERROMAGNETISM - A structure includes an electronically controllable ferromagnetic oxide structure that includes at least three layers. The first layer comprises STO. The second layer has a thickness of at least about 3 unit cells, said thickness being in a direction substantially perpendicular to the interface between the first and second layers. The third layer is in contact with either the first layer or the second layer or both, and is capable of altering the charge carrier density at the interface between the first layer and the second layer. The interface between the first and second layers is capable of exhibiting electronically controlled ferromagnetism. | 01-21-2016 |
20150379900 | MODULAR, WIRELESS, DRUG SIMULANT INJECTION SENSOR SYSTEM AND METHODS OF EMPLOYING - A device for monitoring the position of a plunger member slidingly engaged with a main body of a syringe includes a housing structured to be selectively coupled to the main body in a readily removable manner and a monitoring system disposed at least partially on or in the housing. The monitoring system is structured to detect the absolute position of the plunger member with respect to the main body in a manner which does not require any mechanical linkage with the plunger member. | 12-31-2015 |
20150377867 | MULTIPARAMETRIC METHOD FOR ASSESSING IMMUNE SYSTEM STATUS - The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event. | 12-31-2015 |
20150376595 | Method for Engineering Three-Dimensional Synthetic Vascular Networks Through Mechanical Micromachining and Mutable Polymer Micromolding - The present invention relates generally to a method that is used to create three-dimensional synthetic vascular networks. Micromachining and molding techniques are used to create a template in a shape that mimics a biological network. Cellular material can be seeded around the template or a space created by the template and grown into an engineered tissue-construct. | 12-31-2015 |
20150374736 | URIDINE DIPHOSPHATE COMPOUNDS AS MOBILIZERS OF HEMATOPOIETIC PROGENITOR CELLS - The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobillizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients. | 12-31-2015 |
20150374633 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY - A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days. | 12-31-2015 |
20150371023 | USAGE MODELING - Embodiments of techniques or systems for usage modeling or gesture based authentication are provided herein. Actions of a user may be captured, classified, and utilized to generate an authentication scheme for a device based on gesture recognition, gesture analysis, or action analysis. Training data may be determined based on actions deemed to be training actions and one or more action models may be generated based on the training data. An action model may be indicative of how a user performs a particular or predetermined action. When a security mode is enabled, usage actions may be recorded and usage data may be extracted or determined based on the usage actions. A usage action may be identified and corresponding usage data may be compared with training data from an appropriate action model. An identity of a user associated with the usage action may be determined based on this comparison. | 12-24-2015 |
20150367033 | INJECTABLE PERIPHERAL NERVE SPECIFIC HYDROGEL - The present invention relates to a peripheral nerve-specific hydrogel material, which is deliverable in a minimally invasive fashion, sustains the growth of neurons, and speeds recovery following surgical reconstruction. | 12-24-2015 |
20150344971 | METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA - The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment. | 12-03-2015 |
20150335707 | USE OF SLURP1 AS AN IMUNOMODULATORY MOLECULE IN THE OCULAR SURFACE - Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation. | 11-26-2015 |
20150325311 | LOW-POWER PULSE WIDTH ENCODING SCHEME AND COUNTER-LESS SHIFT REGISTER THAT MAY BE EMPLOYED THEREWITH - A method of decoding, an encoded signal includes steps of receiving the encoded signal, creating a decoding signal by delaying the encoded signal by a predetermined amount of time Δ, sampling the encoded signal using the decoding signal, and determining a value of each of a plurality of decoded bits represented by the encoded signal based on the sampling. Also, a method of operating a shift register wherein the shift register has an initialization state wherein a first binary symbol is stored in a first position and a second binary symbol different than the first binary symbol is stored in each of one or more intermediate positions and a last position. The method includes determining that the shift register is full responsive to detecting that the first binary symbol has been stored in either one of the intermediate positions or the last position. | 11-12-2015 |
20150322202 | METHODS OF ELECTROSPINNING AND COMPOSITIONS MADE THEREFROM - Disclosed herein are methods of electrospinning poly(glycerol sebacate) (PGS) which allow stable PGS fibers and fibrous PGS constructs, scaffolds and grafts to be formed. In one example, a disclosed method includes generating PGS fibers by blending PGS prepolymer with a heat resistant synthetic carrier polymer, wherein the blend is electrospun into micro-or nano-fibers, and the PGS prepolymer is cross-linked into PGS with heat without using chemical cross-linkers. In another example, a disclosed method includes electrospinning a PGS and gelatin blend, wherein the PGS and gelatin composition are cross-linked by heat curing without using chemical cross-linkers. In another example, the method includes preparing an electrospinning precursor solution comprising blending PGS prepolymer with with poly(lactic-co-glycolic acid) (PLGA) and a chemical cross-linker; electrospinning the prepared blend; and exposing the electrospun blend to an organic solvent to remove the PLGA. | 11-12-2015 |
20150310254 | SYSTEM AND METHOD FOR AUTOMATED IDENTIFICATION OF ABNORMAL CILIARY MOTION - A method of classifying ciliary motion includes receiving digital video data representing the ciliary motion generated by an image capture device, wherein the digital video data includes a plurality of frames. The method further includes receiving an indication of a region of interest applicable to each of the frames, wherein the region of interest includes a plurality of pixels in each of the frames, calculating time series elemental motion data for at least one elemental motion parameter for the region of interest based on the digital video data, and using the time series elemental motion data to classify the ciliary motion. | 10-29-2015 |
20150307582 | ENGINEERED RECEPTORS AND THEIR USE - Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed. The use of these compositions and nanoparticles, such as for the treatment of pain, cystic fibrosis and asthma, is also disclosed. | 10-29-2015 |
20150307512 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY - The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing. | 10-29-2015 |
20150306183 | FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE - Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood. | 10-29-2015 |
20150306074 | FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS - Compounds of formula I and their metabolites are potent mediators of an inflammatory response: | 10-29-2015 |
20150305609 | METHOD AND APPARATUS FOR AIDING IN THE DIAGNOSIS OF OTITIS MEDIA BY CLASSIFYING TYMPANIC MEMBRANE IMAGES - A method of aiding the diagnosis of otitis media in a patient includes obtaining image data in a processor apparatus of a computing device, the image data being associated with at least one electronic image of a tympanic membrane of the patient, calculating a plurality of image features, each image feature being calculated based on at least a portion of the image data, classifying the at least one electronic image as a particular type of otitis media using the plurality of image features, and outputting an indication of the particular type of otitis media. Also, a system for implementing such a method that includes an output device and a computing device. | 10-29-2015 |
20150290308 | MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA - It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein. | 10-15-2015 |
20150283109 | LIPASE INHIBITORS FOR THE TREATMENT OF PANCREATITIS AND ORGAN FAILURE - The present invention relates to methods for treating pancreatitis and/or organ failure comprising administering, to a subject in need of such treatment, an effective amount of a lipase inhibitor. It is based, at least in part, on the discoveries that lipotoxicity contributes to inflammation, multisystem organ failure, necrotic pancreatic acinar cell death and in acute pancreatitis, and that inhibition of lipolysis was able to reduce indices associated with these conditions. Accordingly, in various embodiments, the present invention provides for methods and compositions for limiting lipotoxicity and thereby reducing the likelihood of poor outcomes associated with acute pancreatitis and other severe systemic conditions, especially in obese individuals. | 10-08-2015 |
20150276983 | EFFICIENT WHITE LIGHT SCATTERING PHOTONIC BANDGAP CRYSTAL - A photonic bandgap crystal or photonic bandgap crystal material comprising a self-assembled crystalline colloidal array (CCA) of monodisperse spherical particles having a face-centered-cubic (fcc) or a body-centered-cubic (bcc) lattice dispersed in a medium. The photonic bandgap crystal or photonic bandgap crystal material has a photonic bandgap for light in the visible and near-IR or a photonic bandgap for light in the visible range of wavelengths less than about 700 nm. | 10-01-2015 |
20150265626 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION - The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a | 09-24-2015 |
20150251106 | NANO SEEDING TOOLS TO GENERATE NANOMETER SIZE CRYSTALLIZATION SEEDS - A kit and a method for using the kit to generate nanoseeds from protein nanocrystals and aggregates is disclosed. The method comprises mixing a plurality of beads with a protein nanocrystal or aggregate, and agitating the mixture to generate the nanoseeds. Nanoseeds made by disclosed embodiments may be of a high quality, as evaluated by TEM, and can be used to produce high quality protein crystals. Additionally, spectroscopic techniques, such as UV fluorescence and/or brightfield microscopy can be used to identify aggregates suitable to produce nanoseeds. | 09-10-2015 |
20150250809 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS - The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role. | 09-10-2015 |
20150240317 | FUNCTIONAL GENOMICS SCREENING PLATFORM FOR HEAD AND NECK CANCER - The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s). | 08-27-2015 |
20150232526 | USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION - Disclosed herein are methods of using relaxin polypeptides and analogs, or nucleic acid molecules encoding such polypeptides to treat or inhibit atrial fibrillation. | 08-20-2015 |
20150231180 | TRABECULAR MESHWORK STEM CELLS - Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject. | 08-20-2015 |
20150230453 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION - Disclosed herein are solutions for use with machine perfusion of one or more organs. In some embodiments, the solutions comprise acellular cross-linked hemoglobin in a physiologically acceptable medium. Also disclosed herein are methods for machine perfusion of one or more organs, for example utilizing the disclosed perfusion solutions. In some embodiments, the methods include perfusing an organ with an oxygenated solution (such as the disclosed solutions) which is at a temperature between about 12-37° C., for example at a temperature of about 21° C. | 08-20-2015 |
20150216824 | Treatment of Medium-Chain Acyl-CoA Dehydrogenase Deficiency - The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency. | 08-06-2015 |
20150204728 | SPATIAL-DOMAIN LOW-COHERENCE QUANTITATIVE PHASE MICROSCOPY - Systems, methods and other embodiments associated with spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM) are described herein. SL-QPM can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses. The nuclear nano-morphology derived from SL-QPM offers significant diagnostic value in clinical care and subcellular mechanistic insights for basic and translational research. Techniques that provide for depth selective investigation of nuclear and other cellular features are disclosed. | 07-23-2015 |
20150194066 | MEDICAL DEVICE TRAINING SYSTEMS AND METHODS OF USING - A smart peripheral device for use in a medical training system. The medical training system having a processing device, software to emulate aspects of a medical device and a display in communication therewith. The processing device, software and display providing an interactive interface which emulates a portion of the medical device. The smart peripheral device includes a physical structure adapted to imitate a functional component of a medical device and at least one sensor adapted to measure an aspect of user performance, such as position, pressure or other physical variable. | 07-09-2015 |
20150191786 | Genetic Polymorphisms Associated With Advanced Lung Diseases - The present invention relates to methods and compositions that may be used to predict the risk of an individual, for example a smoker, for developing chronic obstructive pulmonary disease (“COPD”), emphysema or idiopathic pulmonary fibrosis (“IPF”). | 07-09-2015 |
20150191698 | ADIPOSE-DERIVED STEM CELLS AND LATTICES - The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures. | 07-09-2015 |
20150190400 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION - This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele. | 07-09-2015 |
20150175607 | P62-ZZ CHEMICAL INHIBITOR - A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound. | 06-25-2015 |
20150152041 | FBXO3 INHIBITORS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 06-04-2015 |
20150150853 | PROMOTING SLEEP USING AT1 RECEPTOR BLOCKERS - The present invention relates to the use of an Angiotensin II type 1 (AT1) receptor blocker for promoting sleep and/or the treatment of insomnia. It is based, at least in part, on the results of experiments performed using a validated rat model of stress-induced insomnia in which candesartan was found to ameliorate sleep disturbances induced by stress. Further, it was observed that this effect seems to be caused by blockade of AT1 receptors located in several brain regions that are key components of the neural circuitry activated during insomnia. In contrast to currently marketed treatments for insomnia, the AT1 receptor blocker was found to restore normal sleep without inhibiting REM sleep and/or inducing atypical wave components in the EEG. | 06-04-2015 |
20150141488 | SMALL MOLECULE INHIBITORS OF RNA BINDING MOTIF (RBM) PROTEINS FOR THE TREATMENT OF ACUTE CELLULAR INJURY - A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: | 05-21-2015 |
20150139965 | MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES - The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes. | 05-21-2015 |
20150132356 | BIOMIMETIC COATING OF MAGNESIUM ALLOY FOR ENHANCED CORROSION RESISTANCE AND CALCIUM PHOSPHATE DEPOSITION - The invention relates to biomimetic peptide-containing compositions for use, in particular, for application and or deposition on a magnesium alloy, e.g., substrate, to at least partially coat a surface of the magnesium alloy. The invention also relates to the coated magnesium alloy which is particularly useful for tissue and bone repair and regeneration applications, such as, for constructing medical implant devices. | 05-14-2015 |
20150126846 | SKIN SCREW ELECTRODES - Electrodes providing excellent recording and physical stability. Electrodes are disclosed that may include a plurality of small teeth that possess a novel design shape and orientation. The shallow and relatively long teeth run parallel to the rim of the electrode that presses against the patient's skin. When the electrode is twisted onto skin, the tiny teeth penetrate the stratum corneum and move nearly horizontally under the stratum corneum, thus anchoring the electrode securely to the skin. The electrodes cause minimal discomfort to the patient since the small teeth do not extend to the pain fibers which are located in deeper layers of the skin. The electrodes may be fabricated in a variety of geometries including cylindrical, disk, and blunt bullet or top shapes. In some instances, the electrodes may be connected to detachable leads having magnetic properties. | 05-07-2015 |
20150119468 | PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY - Methods are provided herein for treating an individual having a disease, disorder or condition affecting the lungs, wherein said disease, disorder, or condition of the lung is an acute lung injury. In specific embodiments, the acute lung injury is chemical induced acute lung injury (CIALI). In some embodiments, the methods are provided for treating or protecting a subject from chemical induced acute lung injury that include administering to the subject a therapeutically effective amount of a phosphatase located on chromosome 10 (PTEN) inhibitor such as N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl)pivalamide (SF1670). In some embodiments, the method products a subject from CAILI or reduces CAILI that results from a subsequent exposure to a chemical that induces chemical induced acute lung injury. | 04-30-2015 |
20150112144 | ADAPTIVE OPTICAL LASER BEAM STEERING THROUGH ENDOSCOPE FOR LASER SURGERY IN KIDNEY - A lightguide is configured to transmit a scanned and/or focused processing beam to a target. The processing beam has a wavefront amplitude and phase set by a spatial light modulator. Suitable wavefront characteristics are obtained based on portions of the processing beam returned to a detector through the lightguide. A beam path can be detected at a first, reduced power, and processing along the beam path performed at a second, higher optical power. | 04-23-2015 |
20150105882 | INERTIAL MEASUREMENT OF SPORTS MOTION - Systems and methods of motion tracking are disclosed that can be used in connection with sports motion. Such a method can include placing one or more inertial measurement units (IMUs) on at least one of a person or one or more pieces of equipment, recording motion data associated with the at least one of the person or the one or more pieces of equipment, and synchronizing the recorded motion data. The method can also include analyzing the synchronized motion data in connection with a motion standard, and generating feedback based at least in part on the analyzed motion data. | 04-16-2015 |
20150104807 | KITS FOR DIAGNOSTIC AND THERAPEUTIC USES OF AUGMENTER OF LIVER REGENERATION IN INFLAMMATORY CONDITIONS - The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a method of treating sepsis, traumatic/hemorrhagic shock and inflammation by inhibiting ALR. | 04-16-2015 |
20150094564 | INTELLIGENT ALGORITHMS FOR TRACKING THREE-DIMENSIONAL SKELETAL MOVEMENT FROM RADIOGRAPHIC IMAGE SEQUENCES - Systems and methods are disclosed that improve conventional tracking and modeling methods for determining three-dimensional bone motion from sequences of radiographic images. These enhancements significantly improve the speed, reliability and accuracy for bone motion tracking. Techniques used in various embodiments include multi-bone hierarchical techniques, time coherent approaches, simultaneous optimization of the entire motion sequence and improved initial estimates of bone motion paths. | 04-02-2015 |
20150094547 | SYSTEM AND METHOD FOR STORING INFORMATION RELATING TO A MEDICAL IMPLANT DEVICE - A method of storing information relating, to a medical implant device having a number of implant elements includes receiving a first image, the first image showing a surgical site and the medical implant device, creating a second image using the first image and a stored list of possible implant elements, the second image showing the surgical site and the medical implant device with a number of labels associated therewith, wherein each of the labels is associated with a respective one of the implant elements and indicates one of the possible implant. elements from the stored list, and storing the second image on an transponder device structured to be attached to the medical implant device or at a medically appropriate site on or within a patient's body. | 04-02-2015 |
20150088183 | SURGICAL TOOL MONITORING SYSTEM AND METHODS OF USE - A device for simultaneously monitoring the health of surgical drills and detecting proximity to critical structures during surgery is described herein. By using various sensors (e.g. microphones, accelerometers, temperature sensors, etc.), signals from the drill can be measured and analyzed. The processed signals can then be used to indicate the proximity of the drill bit to critical structures, such as the patient's brain, and identify drill health issues (e.g. worn bearings, misaligned rotational axis, etc.). | 03-26-2015 |
20150081328 | SYSTEM FOR HOSPITAL ADAPTIVE READMISSION PREDICTION AND MANAGEMENT - A method of determining a probability of readmission of a patient includes receiving patient data from a plurality of information sources; calculating the probability of readmission of the patient based on the patient data and an adaptive readmission risk model; and providing the probability of readmission of the patient to a medical provider. | 03-19-2015 |
20150080229 | PLASMA MICRORIBONUCLEIC ACIDS AS BIOMARKERS FOR ENDOMETRIOSIS AND ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCER - The present invention relates to methods and compositions for differentiating between absence of disease, endometriosis, and EAOC or serous ovarian cancer in a subject. It is based, at least in part, on the discovery that certain microRNAs are associated with each of these conditions. | 03-19-2015 |
20150065488 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION - The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant α1-antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in α1-antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease. | 03-05-2015 |
20150064724 | BIOMARKERS FOR PROGNOSES OF PULMONARY DISEASES - The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment. | 03-05-2015 |
20150050647 | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse - The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression. | 02-19-2015 |
20150045304 | BONE SUBSTITUTE NANOCOMPOSITES AND METHODS OF SYNTHESIS USINGMULTIPHOSPHORYLATED PEPTIDES - The invention relates to peptides including DEDE(SSD) | 02-12-2015 |
20150044655 | DRUG SIMULANT RECOGNITION SYSTEM AND METHOD OF EMPLOYING - A system for identifying a drug simulant includes an electronic sensing system structured to measure the value of an inherent property of the drug simulant; a processing unit in electrical communication with the electronic sensing system; and a memory unit in communication with the processing unit, the memory unit having a look-up table including a range of values of the inherent property of a given fluid and corresponding names of simulated drugs associated with each value. The processor is structured to identify a name of the simulated drug corresponding to the drug simulant by receiving signals indicative of the value of the measured inherent property from the sensing system and comparing the value to the look-up table in the memory. | 02-12-2015 |
20150038561 | MITOCHONDRIAL TARGETED RNA EXPRESSION SYSTEM AND USE THEREOF - Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | 02-05-2015 |
20150030628 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR INFLUENZA - The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals. | 01-29-2015 |
20150018346 | COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AGING AND DEGENERATIVE DISORDERS - The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder. | 01-15-2015 |
20150017262 | INHIBITION OF DYNAMIN RELATED PROTEIN 1 TO PROMOTE CELL DEATH - The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies. | 01-15-2015 |
20150010832 | CATHODES AND ELECTROLYTES FOR RECHARGEABLE MAGNESIUM BATTERIES AND METHODS OF MANUFACTURE - The invention relates to Chevrel-phase materials and methods of preparing these materials utilizing a precursor approach. The Chevrel-phase materials are useful in assembling electrodes, e.g., cathodes, for use in electrochemical cells, such as rechargeable batteries. The Chevrel-phase materials have a general formula of Mo | 01-08-2015 |
20140378444 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 12-25-2014 |
20140377213 | WET-ELECTROSPUN BIODEGRADABLE SCAFFOLD AND USES THEREFOR - A cell growth matrix is provided that comprises a biodegradable elastomeric polymer electrodeposited concurrently with a sprayed or electrosprayed liquid that is a physiological solution or which comprises a mammalian blood product such as serum, plasma or platelet rich plasma. The matrix is useful as a cell-growth matrix and for repair of a tissue in a mammal, for instance by implantation in a mammal at a site in need of repair, such as in an abdominal wall. | 12-25-2014 |
20140375172 | FLEXIBLE MOLECULAR PIEZOELECTRIC DEVICE - A piezoelectric material, comprising: a piezoelectric self-assembling monolayer of oligopeptides; a conductive surface; and a substrate, wherein the conductive surface is located between the piezoelectric self-assembling monolayer of oligopeptides and the substrate. A touch sensitive device, comprising: a first piezoelectric material, comprising: a piezoelectric self-assembling monolayer of oligopeptides containing a dipole moment; a conductive surface; and a substrate; a second piezoelectric material, comprising: a piezoelectric self-assembling monolayer of oligopeptides containing a dipole moment; a conductive surface; and s substrate, wherein the oligopeptides making up the self-assembling monolayer of the first and second piezoelectric materials, respectively, have the same amino acid sequence but have an equal and opposite dipole moment. | 12-25-2014 |
20140371259 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY - A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof. | 12-18-2014 |
20140363801 | MEDICAL TRAINING SYSTEM AND METHOD OF EMPLOYING - A medical training method includes generating an image of a first level of anatomical structures, displaying the image in a correct registration in a first display area on the surface of a portion of a simulated body, detecting a user input associated with the portion of the simulated body, and responsive to said detecting, generating and displaying at least one visual image in a correct registration in the first display area. A system for carrying out such method is also provided. | 12-11-2014 |
20140357549 | NOVEL INHIBITORS OF NOX1 - The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer. | 12-04-2014 |
20140356331 | INJECTABLE CNS-DERIVED ECM FOR TISSUE RECONSTRUCTION - Methods useful for preparing central nervous system (CNS) derived extracellular matrix (ECM) materials, including powders and gels are provided. Also provided are CNS ECM preparations prepared according to those methods, and methods of treating a patient or mammal with CNS injury. | 12-04-2014 |
20140353378 | LOW-POWER PULSE WIDTH ENCODING SCHEME AND COUNTER-LESS SHIFT REGISTER THAT MAY BE EMPLOYED THEREWITH - A method of decoding an encoded signal includes steps of receiving the encoded signal, creating a decoding signal by delaying the encoded signal by a predetermined amount of time Δ, sampling the encoded signal using the decoding signal, and determining a value of each of a plurality of decoded bits represented by the encoded signal based on the sampling. Also, a method of operating a shift register wherein the shift register has an initialization state wherein a first binary symbol is stored in a first position and a second binary symbol different than the first binary symbol is stored in each of one or more intermediate positions and a last position. The method includes determining that the shift register is full responsive to detecting that the first binary symbol has been stored in either one of the intermediate positions or the last position. | 12-04-2014 |
20140350472 | DISSOLVABLE MICRONEEDLE ARRAYS FOR TRANSDERMAL DELIVERY TO HUMAN SKIN - A method of forming a microneedle array can include forming a sheet of material having a plurality of layers and micromilling the sheet of material to form a microneedle array. At least one of the plurality of layers can include a bioactive component, and the microneedle array can include a base portion and plurality of microneedles extending from the base portion. | 11-27-2014 |
20140348778 | REVERSE THERMAL GELS AND THEIR USE IN CELL THERAPY - Methods are disclosed herein for increasing survival of transplanted cells, either in vitro or in vivo. In additional embodiments, methods are disclosed for treating a subject with a spinal cord injury or a neurodegenerative disorder. The methods include administering to a subject a therapeutically effective amount of cells, such as bone marrow stromal cells, and a therapeutically effective amount of a reverse thermal gel composition. The reverse thermal gel compositing includes a triblock copolymer, or pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant active groups, blocked active groups or active agents and B is a hydrophilic block, wherein the composition is a gel at 25° C.-40° C. and a liquid solution at a lower temperature. | 11-27-2014 |
20140335547 | Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation - The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression. | 11-13-2014 |
20140331341 | AUTOMATED HIGH-CONTENT LIVE ANIMAL DRUG SCREENING USING C. ELEGANS - The present invention relates to methods and compositions for high content drug screening in | 11-06-2014 |
20140329702 | METHOD OF AMPLIFYING A NUCLEIC ACID - A nucleic acid amplification method is provided, along with kits useful in performing the amplification method. | 11-06-2014 |
20140321798 | OPTICAL SENSOR EMPLOYING A REFRACTIVE INDEX ENGINEERED METAL OXIDE MATERIAL - An optical sensor device includes an optical waveguide portion having a core, the core having a first refractive index, and a functional material layer coupled to the optical fiber portion, the functional material layer being made of a metal oxide material, the functional material layer being structured to have a second refractive index, the second refractive index being less than the first refractive index. The functional material layer may be a nanostructure material comprising the metal oxide material with a plurality of holes or voids formed therein such that the functional material layer is caused to have the second refractive index. | 10-30-2014 |
20140314816 | STABILIZED STAT3 DECOY OLIGONUCLEOTIDES AND USES THEREFORE - The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer. | 10-23-2014 |
20140314758 | IMMUNOGENIC TUMOR ASSOCIATED STROMAL CELL ANTIGEN PEPTIDES AND METHODS OF THEIR USE - Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed. | 10-23-2014 |
20140309726 | BIODEGRADABLE VASCULAR GRAFTS - Disclosed herein are biodegradable scaffolds for in situ tissue engineering. In some examples, biodegradable vascular grafts and methods of fabricating and uses of such are disclosed. In some examples, a vascular graft includes a biodegradable scaffold including a biodegradable polyester tubular core, a biodegradable polyester electrospun outer sheath surrounding the biodegradable polyester tubular core and/or a thromboresistant agent, such as heparin, coating the biodegradable scaffold. The disclosed vascular grafts can be used for forming a blood vessel of less than 6 mm, including, but not limited to a coronary or peripheral arterial. | 10-16-2014 |
20140309303 | NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES - Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ. | 10-16-2014 |
20140302548 | MULTIPARAMETRIC METHOD FOR ASSESSING IMMUNE SYSTEM STATUS - The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event. | 10-09-2014 |
20140296695 | SELECTIVE ZERO-QUANTUM COHERENCE TRANSFER (SEL-ZQC) METHOD FOR METABOLITE IMAGING IN A POORLY SHIMMED MAGNET FIELD WITHOUT SUSCEPTIBILITY ARTIFACT - Systems and methods employing spin editing techniques to improve magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopic imaging (MRSI) are discussed. Using these spin editing techniques, magnetic resonance signals of one or more non-target chemicals (chemicals whose signals are to be filtered out or suppressed) chemicals can be suppressed, so that the signal(s) of a set of target chemicals can be obtained without signals from the one or more non-target chemicals. Information about and differences between the molecular topologies of the first set of chemicals and the one or more unwanted chemicals can be used to design a sequence that suppresses the one or more unwanted chemicals while allowing acquisition of signal(s) from the first set of chemicals. These techniques can be employed to recover sharp peaks despite magnetic field inhomogeneities and susceptibility effects. | 10-02-2014 |
20140294918 | Matricryptic ECM Peptides for Tissue Reconstruction - Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone. | 10-02-2014 |
20140294270 | DIRECTIONAL DIFFUSION FIBER TRACKING - Systems and methods facilitating high definition fiber tracking are disclosed. These systems and methods can utilize a directional Axonal Volume (dAV) value that can quantify the direction and volume of anisotropic water diffusion in axons to assess brain connection integrity. dAV provides a robust and anatomically interpretable measurement of connectivity strength of axon tracts. One method include receiving diffusion magnetic resonance imaging (dMRI) data, quantifying a vector axonal directional diffusion axon volume while removing extracellular isotropic water, segmenting fiber tracks from the data, voxelizing the fiber tracks into voxels, determining voxel dAV values for each voxel and directions, and determining fiber dAV values for each fiber track based on voxel dAV values. This non-invasive method can measure strength and integrity of brain tracts. Such measurements aid in detection of connection disorders like traumatic brain injury and mapping the location of brain tracts and their projection fields to improve neurosurgical outcomes. | 10-02-2014 |
20140287243 | SUPERHYDROPHOBIC COATINGS - A coating composition comprising a colloidal suspension comprising a fluoropolymer and fluorophilic particles in a liquid solvent, wherein the solvent comprises a fluorocarbon, a semifluorous material, or a combination thereof. Also disclosed is a substrate comprising a coated surface, wherein the coated surface comprises a fluorophilic silica particle doped—fluoropolymer film. Further disclosed is a method comprising fluorinating silica particles and preparing a colloidal suspension comprising a fluoropolymer and the fluorinated silica particles in a liquid solvent, wherein the solvent comprises a fluorocarbon, a semifluorous material, or a combination thereof. | 09-25-2014 |
20140257075 | MEASURING AQUEOUS HUMOR OUTFLOW - Technologies are provided to estimate in vivo aqueous humor outflow for a subject. The method can include: preparing a virtual casting of the outflow network of the subject by use of background subtraction and contrast enhancement; tracing network terminal branches in said reduced virtual casting; obtaining Doppler data for at least some of the terminal branches, to calculate a fluid velocity within each of such terminal branch; then pairing each fluid velocity for each such terminal branch with a measurement of cross-sectional area for that terminal branch, thereby to provide a plurality of volumetric flow values; and integrating over the plurality to obtain a volumetric estimate of aqueous humor outflow for the subject. | 09-11-2014 |
20140256801 | PERIPHERALLY DELIVERED GLUTAMIC ACID DECARBOXYLASE GENE THERAPY FOR SPINAL CORD INJURY PAIN - The invention provides a method of treating spinal cord injury pain or peripheral neuropathic pain in a mammal comprising administering to a mammal a vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein in an amount effective to treat spinal cord injury pain or peripheral neuropathic pain. | 09-11-2014 |
20140256654 | BIFUNCTIONAL COMPOUNDS - A compound having the formula: | 09-11-2014 |
20140255952 | DEGRADABLE CARBON NANOTUBE-CONTAINING BIOSENSORS AND METHODS FOR TARGET CLINICAL MARKER DETECTION - The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers. | 09-11-2014 |
20140249595 | Methods and Systems for Achieving a Physiological Response by Pudendal Nerve Stimulation and Blockade - Methods and apparatus are therefore provided herein for stimulating a desired physiological effect. The methods and apparatus can be used to control micturition, defecation and/or ejaculation. The methods and apparatus also can be used to control pain in the lower pelvic region, for example and without limitation, interstitial cystitis. The methods and apparatus also can be used to increase sexual sensation. | 09-04-2014 |
20140249209 | METHODS FOR THE TREATMENT AND PREVENTION OF LIVER DISEASE - The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4α; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival. | 09-04-2014 |
20140248288 | BIODEGRADABLE METAL ALLOYS - The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The compositions are prepared by vacuum induction/crucible melting together the components and casting the melted mixture in a preheated mild steel/copper mold. In certain embodiments, the compositions of the invention are particularly useful for forming medical devices for implantation into a body of a patient. | 09-04-2014 |
20140248232 | BIODEGRADABLE, NON-THROMBOGENIC ELASTOMERIC POLYURETHANES - A method of forming an implantable article includes providing a biodegradable polymer including anti-thrombogenic groups along the length of the biodegradable polymer, biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable article, and reacting at least a portion of the plurality of functional groups with the reactive functional groups on the surface of the implantable article. | 09-04-2014 |
20140243911 | BIODEGRADABLE, MAGNESIUM-CONTAINING BONE SCREWS, METHODS FOR THEIR PREPARATION AND MEDICAL APPLICATIONS THEREFOR - The invention relates to a biodegradable, magnesium-containing bone screw for implanting into a patient body for use in medical applications, such as, orthopedic, craniofacial and cardiovascular surgery. The bone screw has a head, shaft and tip. The thickness of the head is greater than the thickness of conventional bone screws. The shaft includes both a non-threaded and a threaded portion. The tip is non-threaded and pointed, such as, conical in shape. The composition of the bone screws provide for improved biodegradability and biocompatibility, and the features of the structure of the bone screws facilitate guidance and placement during implantation as well as reduce the potential for mechanical failures. | 08-28-2014 |
20140243215 | METHOD FOR DIAGNOSING RENAL DISEASES OR PREDISPOSITIONS - The invention provides a method of diagnosing a disease or a predisposition to contract a disease by assaying for mutations of uromodulin (UMOD) within a test subject or patient. The presence of a mutation in the UMOD supports a diagnosis of a disease or a predisposition to contract a disease within the patient. | 08-28-2014 |
20140234324 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 08-21-2014 |
20140220590 | METHODS OF USING BENZOTHIAZOLE DERIVATIVE COMPOUNDS AND COMPOSITIONS - This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s). | 08-07-2014 |
20140220061 | YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF - Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a | 08-07-2014 |
20140213517 | Thermoresponsive, Biodegradable, Elastomeric Material and Uses Therefor - Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers. | 07-31-2014 |
20140200824 | K-PARTITE GRAPH BASED FORMALISM FOR CHARACTERIZATION OF COMPLEX PHENOTYPES IN CLINICAL DATA ANALYSES AND DISEASE OUTCOME PROGNOSIS - Systems and methods are disclosed that can analyze relationships between parameters in data matrices (e.g., collections of individual profiles). A graph topology can be defined on a data matrix with partitions as variables and vertices in all partitions and their potentials and edges as the co-occurrence of a pair of variable values in a profile. Individual graphs can be constructed from data and value co-occurrences for every profile, and a study data graph made as a union of all individual graphs. Heterogeneity Landmarks (HLs) can be determined from the study data graph, and graph-graph distances between individual graphs and all HLs. These distances can be used for prognoses based on similarity of a profile to one or more HLs. | 07-17-2014 |
20140194365 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 07-10-2014 |
20140187901 | ELECTRODE SYSTEMS, DEVICES AND METHODS - An electrode system include a flowable and cohesive surface contact element comprising a hydrophilic polymer swollen with an electrolyte fluid, the contact element having a Q′ ratio of at least 5 as defined by the equation | 07-03-2014 |
20140179595 | APOLIPOPROTEIN E POLYPEPTIDES AND THEIR USE - Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods | 06-26-2014 |
20140178451 | ACTIVATORS OF CXCR3 FOR THE TREATMENT OF ANGIOPATHIES OF THE EYE - The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof. | 06-26-2014 |
20140170121 | Neural Scaffolds - Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented. | 06-19-2014 |
20140163111 | POROUS BIOMOLECULE-CONTAINING METAL-ORGANIC FRAMEWORKS - The invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release. | 06-12-2014 |
20140161877 | PEDERIN AND PSYMBERIN AGENTS - Compounds that include a pederin, psymberin or pederin/psymberin chimera scaffold. The pederin scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The psymberin scaffold includes a substituent at the C8 and/or C11 positions that may include a linker that may be conjugated to a targeting moiety. The pederin/psymberin chimera scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The pederin, psymberin or pederin/psymberin chimera scaffold may be modified to include substituents at positions other than the C10 or C13 of pederin, or the C8 and C11 of psymberin. | 06-12-2014 |
20140161726 | Reconstitutable Microsphere Compositions Useful As Ultrasonic Contrast Agents - Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous sugar) in specified amounts that reduce aggregation of the particles comprising the suspension. | 06-12-2014 |
20140148868 | Automated Assessment of Atrioventricular and Ventriculoatrial Conduction - A method discriminates between ventricular arrhythmia and supraventricular arrhythmia by determining the direction of an electrical signal conducted through the atrioventricular node. An implantable cardiac defibrillator provides atrioventricular and ventriculoatrial pacing bursts to determine if an arrhythmia with a 1:1 atrial to ventricular relationship is due to ventricular tachycardia or supraventricular tachycardia. This discrimination capability reduces the incidence of inappropriate shocks from dual-chamber implantable cardiac defibrillators to near zero and provides a method to differentially diagnose supraventricular tachycardia from ventricular tachycardia. | 05-29-2014 |
20140147938 | NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PYRENE BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN - The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate (I) having the formula: wherein B is a group which is present on any of the ten carbon atoms of the pyrene structure represented in (I) susceptible to bear a substituent, and is represented by the following group: —(CH2) | 05-29-2014 |
20140147459 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA - Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 05-29-2014 |
20140142039 | Vasoactive lntestinal Peptide Release From Microparticles - Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group. | 05-22-2014 |
20140134198 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORE - EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods. | 05-15-2014 |
20140128388 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX - Drug candidates for inhibition of HIV-1 replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-1 viral replication in vitro. | 05-08-2014 |
20140127248 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA - Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 05-08-2014 |
20140127163 | USE OF SLURP1 AS AN IMUNOMODULATORY MOLECULE IN THE OCULAR SURFACE - Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation. | 05-08-2014 |
20140107437 | SYSTEM AND METHOD OF DETERMINING A SUSCEPTIBILITY TO CARDIORESPIRATORY INSUFFICIENCY - A system and method for determining a patient's susceptibility to develop cardiorespiratory instability wherein physiological parameters are analyzed with respect to a dynamics systems model to produce and indicator associated with a probability that the patient will become unstable is provided. | 04-17-2014 |
20140107317 | Selective Targeting Agents for Mitochondria - The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargoes which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. | 04-17-2014 |
20140105820 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES - The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent. | 04-17-2014 |
20140097277 | BIODEGRADABLE IRON-CONTAINING COMPOSITIONS, METHODS OF PREPARING AND APPLICATIONS THEREFOR - The invention relates to biodegradable iron alloy-containing compositions for use in preparing medical devices. In addition, biodegradable crystalline and amorphous compositions of the invention exhibit properties that make them suitable for use as medical devices for implantation into a body of a patient. The compositions include elemental iron and one or more elements selected from manganese, magnesium, zirconium, zinc and calcium. The compositions can be prepared using a high energy milling technique. The resulting compositions and the devices formed therefrom are useful in various surgical procedures, such as but not limited to orthopedic, craniofacial and cardiovascular. | 04-10-2014 |
20140094702 | METHODS AND APPARATUSES FOR MEASURING TISSUE STIFFNESS CHANGES USING ULTRASOUND ELASTICITY IMAGING - A method of evaluating tissue stiffness of a target area includes positioning an ultrasound elasticity imaging apparatus adjacent a surface of an area of tissue where the target area is located and applying a dynamic range of force to the tissue. A plurality of ultrasound beams can be directed at the tissue and a plurality of ultrasound echoes can be acquired from the strained tissue in the target area to calculate an amount of developed strain within the target area. | 04-03-2014 |
20140088300 | Modified siRNA Molecules Incorporating 5-Fluoro-2'-Deoxyuridine Residues to Enhance Cytotoxicity - A synthesized siRNA molecule having the sense strand with one or more uridine bases replaced by one or more respective nucleoside analogs, such as 5-fluoro-2′-deoxyuridine (FdU). | 03-27-2014 |
20140088169 | GENETIC CHANGES IN ATM AND ATR/CHEK1 AS PROGNOSTIC INDICATORS IN CANCER - The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients. | 03-27-2014 |
20140086982 | ORAL THERAPY OF NECROTIZING ENTEROCOLITIS - The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants. | 03-27-2014 |
20140073560 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 03-13-2014 |
20140066332 | METHODS FOR THE DIAGNOSIS OF FETAL DISEASE - Methods are provided for detecting an aneuploidy in a fetus. These methods can be used to detect trisomy 13, 8 or 21, amongst other aneupoloidies. In some embodiments, the methods include selectively purifying fetal DNA from a maternal biological sample using the methylation status of a CpG containing genomic sequence and genotyping the fetus using the purified fetal DNA, thereby detecting aneuploidy in the fetus. | 03-06-2014 |
20140065016 | PARACORPOREAL RESPIRATORY ASSIST LUNG - A paracorporeal respiratory assist lung is configured with an annular cylindrical hollow fiber membrane (fiber bundle) that is rotated at rapidly varying speeds. Fluid (for example, blood) is introduced to the center of the device and is passed radially through the fiber bundle. The bundle is rotated at rapidly changing velocities with a rotational actuator (for example, a motor or magnetic coupling). The rotation of the fiber bundle provides centrifugal kinetic energy to the fluid giving the device pumping capabilities and may create Taylor vortexes to increase mass transfer. Rotation of the fiber bundle increases the relative velocity between the fluid and the hollow fibers and increases the mass transfer. The porosity of the fiber bundle may be varied to enhance gas exchange with the blood. Alternatively, a rotating core may be used with a stationary fiber bundle. | 03-06-2014 |
20140062212 | Wireless Energy Transfer System - A wireless energy transfer system includes a first energy transfer unit having at least one resonant frequency, a second energy transfer unit having the at least one resonant frequency, and a load. The first wireless energy transfer unit includes a first coil magnetically coupled to a first wireless energy transfer cell, and the second wireless energy transfer unit includes a second coil magnetically coupled to a second wireless energy transfer cell. The first coil receives first energy and through the magnetic coupling between the first coil and the first wireless energy transfer cell, the first wireless energy transfer cell is caused to generate second energy, wherein the second wireless energy transfer cell receives the second energy and through the magnetic coupling between the second wireless energy transfer cell and the second coil, the second coil is caused to provide third electromagnetic wave energy to the load. | 03-06-2014 |
20140057832 | USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE - The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness. | 02-27-2014 |
20140057315 | ANTIGEN PRESENTING CELL ASSAY - Disclosed herein are methods for diagnosing or predicting acute cellular and/or humoral rejection in a subject. In one example, a method of assessing organ rejection includes contacting a first sample comprising antigen presenting cells (APCs) obtained from a subject in need of or having received an organ transplant with a donor antigen from a donor under conditions sufficient to induce uptake of the donor antigen; contacting a second sample comprising APCs obtained from the subject in need of or having received an organ transplant with a third-party antigen under conditions sufficient to induce uptake of the third-party antigen; and determining an antigen presenting index by determining a ratio of uptake of the donor antigen in the first sample to uptake of the third-party antigen in the second sample, wherein the ratio of greater than one indicates organ rejection and the APCs are monocytes or monocyte-derived cells. | 02-27-2014 |
20140047569 | Methods of Treating Disorders Associated with Protein Aggregation - The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a | 02-13-2014 |
20140046208 | COMPRESSIVE SAMPLING OF PHYSIOLOGICAL SIGNALS USING TIME-FREQUENCY DICTIONARIES BASED ON MODULATED DISCRETE PROLATE SPHEROIDAL SEQUENCES - A method of sampling and reconstructing an original physiological signal obtained from a subject includes acquiring a number of samples of the original physiological signal, and generating a reconstructed physiological signal using the samples and a time-frequency dictionary, the time-frequency dictionary having bases which are modulated discrete prolate spheroidal sequences. | 02-13-2014 |
20140045821 | PROTEIN KINASE D INHIBITORS - Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity. | 02-13-2014 |
20140045678 | NON-NOBLE METAL BASED ELECTRO-CATALYST COMPOSITIONS FOR PROTON EXCHANGE MEMBRANE BASED WATER ELECTROLYSIS AND METHODS OF MAKING - The invention provides electro-catalyst compositions for an anode electrode of a proton exchange membrane-based water electrolysis system. The compositions include a noble metal component selected from the group consisting of iridium oxide, ruthenium oxide, rhenium oxide and mixtures thereof, and a non-noble metal component selected from the group consisting of tantalum oxide, tin oxide, niobium oxide, titanium oxide, tungsten oxide, molybdenum oxide, yttrium oxide, scandium oxide, cooper oxide, zirconium oxide, nickel oxide and mixtures thereof. Further, the non-noble metal component can include a dopant. The dopant can be at least one element selected from Groups III, V, VI and VII of the Periodic Table. The compositions can be prepared using a surfactant approach or a sol gel approach. Further, the compositions are prepared using noble metal and non-noble metal precursors. Furthermore, a thin film containing the compositions can be deposited onto a substrate to form the anode electrode. | 02-13-2014 |
20140037581 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA - The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases. | 02-06-2014 |
20140037542 | NOVEL THERANOSTIC PLATFORM FOR TARGETED CANCER THERAPY AND DRUG DELIVERY MONITORING - A compound that includes a quaterrylene dye moiety as core, and a dendrimeric shell. For example, the compound may comprise at least four dendronized polyamides covalently attached to a quaterrylene dye. Also disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, comprising A(G) | 02-06-2014 |
20140030694 | OXYGEN DEPLETION DEVICES AND METHODS FOR REMOVING OXYGEN FROM RED BLOOD CELLS - An oxygen depletion device. The device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers. The hollow fibers are adapted to receiving and conveying red blood cells. There is another embodiment of an oxygen depletion device and method for removing oxygen from red blood cells. | 01-30-2014 |
20140018317 | TARGETED NITROXIDE AGENTS - A compound having a structure of: | 01-16-2014 |
20140017309 | ENTERAL ADMINISTRATION OF SORBENT POLYMER FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATION - The invention provides a method of ameliorating inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating. | 01-16-2014 |
20140010811 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 01-09-2014 |
20140005386 | p53-Mdm2 ANTAGONISTS | 01-02-2014 |
20140004161 | BONE SUBSTITUTE COMPOSITIONS, METHODS OF PREPARATION AND CLINICAL APPLICATIONS | 01-02-2014 |
20140004124 | MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA | 01-02-2014 |
20130338212 | Genetic Changes In ATM And ATR/Chek1 As Prognostic Indicators In Cancer - The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients. | 12-19-2013 |
20130331460 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains. | 12-12-2013 |
20130323700 | HYBRID PHYSICAL-VIRTUAL REALITY SIMULATION FOR CLINICAL TRAINING CAPABLE OF PROVIDING FEEDBACK TO A PHYSICAL ANATOMIC MODEL - Systems and methods facilitating training in clinical procedures via mixed reality simulations are disclosed. Such a system can comprise a physical model and a virtual model of an anatomic region associated with the procedure, wherein the virtual model associates tissue types with locations in the physical model. The system can include a tracking component that tracks locations of at least one clinical instrument relative to the models, and an anatomic feedback component that can produce perceptible changes in the physical model based on the interaction between the instrument and virtual model. A clinical device interface can detect outputs of clinical devices like electrical signals, pressure or flow, wherein feedback to the physical model depends on the tracked position of a clinical device and output from the same or different clinical device. Another component can generate feedback effects to the clinical device. Aspects can simulate anesthesiology procedures like local nerve blockade. | 12-05-2013 |
20130321064 | HIERARCHICAL SINGLE MOLECULE SWITCH BASED ON STIMULATED INTERNAL CLUSTER MOTION WITHIN A HOLLOW MOLECULAR CAGE - Systems and methods related to single molecule switching devices are disclosed. One example method can include the step of applying a tunneling current across a tunneling junction. The tunneling junction can include an endohedral fullerene that includes a fullerene cage and a trapped cluster or a trapped atom. Such a method can also include exciting one or more internal motions of the trapped cluster or the trapped atom based at least in part on the tunneling current, and changing the conductance of the endohedral fullerene based at least in part on the one or more excited internal motions. One or more electronic processes can be controlled based at least in part on the changed conductance of the endohedral fullerene. | 12-05-2013 |
20130317376 | Electrocardiogram Reconstruction from Implanted Device Electrograms - A method of reconstruction of the standard 12-lead surface EKG given values of the electrical potential from an implanted medical device is described. This implanted device can be oriented in an arbitrary fashion and reconstruction technique is obtained through physical measurement of the orientation of the implanted device or correlation with a standard 12-lead EKG obtained from the patient. | 11-28-2013 |
20130316959 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 11-28-2013 |
20130316349 | N-METHYLPURINE DNA GLYCOSYLASE AND POLYMERASE BETA AS BIOMARKERS FOR ALKYLATOR CHEMOTHERAPY POTENTIATION - Described herein is the finding that polymerase β (Polβ) and N-methylpurine DNA glycosylase (MPG) can be used as biomarkers to evaluate the sensitivity of a subject to combination therapy that includes treatment with either temozolomide (TMZ) and methoxyamine, or TMZ and a poly(ADP-ribose) polymerase (PARP) inhibitor. Thus, provided herein is a method of determining if a subject will be sensitive to TMZ and methoxyamine, or TMZ and a PARP inhibitor by measuring expression of Polβ and MPG in a sample from the subject and comparing expression of Polβ and MPG in the sample to a control. A decrease in expression of Polβ and an increase in expression of MPG relative to the control indicates the subject is sensitive to TMZ and methoxyamine, or sensitive to TMZ and the PARP inhibitor. | 11-28-2013 |
20130315857 | Kexin-Derived Vaccines to Prevent or Treat Fungal Infections - A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as | 11-28-2013 |
20130309664 | HEAT SHOCK PROTEINS AS AUTOANTIGENS - The present invention relates to methods of diagnosing and/or determining a prognosis for various diseases, including lung diseases such as idiopathic pulmonary fibrosis, chronic obstructive lung disease, and emphysema as well as osteoporosis, comprising detecting the presence of autoantibodies specific for heat shock proteins in a subject. | 11-21-2013 |
20130299773 | LOW VOLTAGE NANOSCALE VACUUM ELECTRONIC DEVICES - An electronic device including a first conducting layer, a second conducting layer, and an insulating layer provided between the conducting layers. At least one side wall extends from the first conducting layer to the second conducting layer and includes at least a portion of the first conducting layer, the second conducting layer and the insulating layer. A bias voltage is applied between the first and second conducting layers, wherein responsive to the bias voltage, a two dimensional electron system is induced at least in one of the first conducting layer and the second conducting layer, and wherein electrons from the two dimensional electron system are emitted from the side wall side wall as a result of Coulombic repulsion and travel in air from the one of the first conducting layer and the second conducting layer to the other of the first conducting layer and the second conducting layer. | 11-14-2013 |
20130289261 | THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN - The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor | 10-31-2013 |
20130287765 | FSH AND FSH RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR INHIBITING OSTEOCLASTIC BONE RESORPTION AND BONE LOSS IN OSTEOPOROSIS - The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders. | 10-31-2013 |
20130278257 | MRI PULSE SEQUENCE BASED ON Q-SPACE TRAJECTORY TECHNIQUE - Systems and methods capable of improving acquisition times associated with obtaining diffusion-weighted magnetic resonance imaging data are discussed. In aspects, multiple points in q-space can be sampled in a single repetition time (TR). Acquisition time can be further increased using other techniques, such as a radial raster or compressed sensing. | 10-24-2013 |
20130274314 | MITOCHONDRIAL TARGETED RNA EXPRESSION SYSTEM AND USE THEREOF - Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | 10-17-2013 |
20130260701 | Method of Controlling RF Transmissions to Mitigate Interference with Critical Care Medical Equipment - Various methods of mitigating RF interference with one or more critical care medical devices is provided, wherein a predetermined threshold energy acceleration value is associated with the one or more critical care medical devices that, if exceeded, will cause RF interference with the one or more critical care medical devices. The methods includes generating and transmitting RF energy, wherein at least a portion of said RF energy follows an RF power profile of power versus time having a particular format designed to mitigate interference. | 10-03-2013 |
20130259865 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF - Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 10-03-2013 |
20130253299 | MONITORING AND REGULATING PHYSIOLOGICAL STATES AND FUNCTIONS VIA SENSORY NEURAL INPUTS TO THE SPINAL CORD - Methods and apparatuses for monitoring and regulating physiological states and functions are disclosed. Several embodiments include application of one or more microelectrode arrays to a dorsal root ganglion for measurement of sensory neuron activity, or stimulation of sensory reflex circuits. The methods and apparatuses can be used, for example, for monitoring or controlling bladder function in a patient. | 09-26-2013 |
20130251668 | USE OF OSTEOPROTEGERIN (OPG) TO INCREASE HUMAN PANCREATIC BETA CELL SURVIVAL AND PROLIFERATION - It is disclosed herein that osteoprotegerin increases human beta cell proliferation and survival. Methods are provided for increasing beta cell proliferation, but contacting a beta cell with an effective amount of osteoprotegrin, a functional fragment, variant or fusion protein thereof. Methods are also provided for treating a human subject with diabetes, comprising administering to the subject a therapeutically effective amount of osteoprotegerin, functional variant or fusion protein thereof. | 09-26-2013 |
20130237685 | LINEAR ASSEMBLIES, BRANCHED ASSEMBLIES, MACROCYCLES AND COVALENT BUNDLES OF FUNCTIONALIZED BIS-PEPTIDES - Provided is a macromolecule comprising two or more functionalized bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the functionalized bis-peptides are covalently attached to one or more functionalized bis-peptides to form linear strings of functionalized bis-peptides, macrocycles of functionalized bis-peptides, three-dimensional networks of functionalized bis-peptides, and combinations of any of these. Also provided is a macromolecule comprising two or more bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the bis-peptides comprise non-functionalized bis-peptides, functionalized bis-peptides or a combination of both functionalized and non-functionalized bis-peptides. In some embodiments, the bis-peptides are covalently attached to one or more bis-peptides to form linear strings of bis-peptides, macrocycles of bis-peptides, three-dimensional networks of bis-peptides, and combinations of any of these. | 09-12-2013 |
20130229663 | SPATIAL-DOMAIN LOW-COHERENCE QUANTITATIVE PHASE MICROSCOPY - Due to potential sampling errors (due to small tissue samples not necessarily directly from the developing tumor) and limited optical resolution (˜1 micron), cancer may be missed or detected too late for optimal treatment, or conservative interpretation of indeterminate findings could lead to unnecessary surgery. The novel technology herein—Spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM)—can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses. The nuclear nano-morphology derived from SL-QPM offers significant diagnostic value in clinical care and subcellular mechanistic insights for basic and translational research. | 09-05-2013 |
20130224761 | NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PORPHYRIN BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN - The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a porphyrin based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate (I) having the formula (I): wherein M is a metal selected in the group comprising Fe, Ni, Zn, Cu, Mn, Cr or Co, B is a group which is present on at least one of the four phenyl group (C | 08-29-2013 |
20130222802 | MANIPULATION, DETECTION, AND ASSAY OF SMALL SCALE BIOLOGICAL PARTICLES - Systems, devices, and methods are presented that facilitate electronic manipulation and detection of submicron particles. A particle manipulation device contains a plurality of electrodes formed on an active semiconductor layer of an integrated circuit chip, where the electrodes and gap spacing between adjacent electrodes is submicron in size. The chip is oriented with its substrate face up, and at least a portion of the substrate is removed from the chip so the electrodes are in close proximity to a fluid chamber(s) placed over the chip, to facilitate manipulation of particles, contained in a buffer solution in the fluid chamber(s), to form a defined pattern. Innovative macro-scale optical detection is employed to detect the submicron particles, where a light beam is applied to the defined pattern, and interaction of the defined pattern with the light beam is detected and evaluated to facilitate detecting the particles. | 08-29-2013 |
20130217038 | MULTIPARAMETRIC METHOD FOR ASSESSING IMMUNE SYSTEM STATUS - The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event. | 08-22-2013 |
20130209571 | BIOENGINEERED HUMAN CORNEAL STROMAL TISSUE - Provided herein is a method of making an aligned ECM scaffold useful in refractive correction of the eye and repair of the cornea. Methods of use of the scaffold as well as a scaffold construct are provided. | 08-15-2013 |
20130204411 | INERTIAL MEASUREMENT OF SPORTS MOTION - Systems and methods of motion tracking are disclosed that can be used in connection with sports motion. Such a method can include placing one or more inertial measurement units (IMUs) on at least one of a person or one or more pieces of equipment, recording motion data associated with the at least one of the person or the one or more pieces of equipment, and synchronizing the recorded motion data. The method can also include analyzing the synchronized motion data in connection with a motion standard, and generating feedback based at least in part on the analyzed motion data. | 08-08-2013 |
20130202579 | USE OF CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE-ALPHA (CCT-ALPHA) AS A BIOMARKER FOR CANCER PROGNOSIS - It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject. | 08-08-2013 |
20130202563 | DECELLULARIZED ADIPOSE CELL GROWTH SCAFFOLD - Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold. | 08-08-2013 |
20130200152 | LOW-POWER PULSE WIDTH ENCODING SCHEME AND COUNTER-LESS SHIFT REGISTER THAT MAY BE EMPLOYED THEREWITH - A method of decoding an encoded signal includes steps of receiving the encoded signal, creating a decoding signal by delaying the encoded signal by a predetermined amount of time Δ, sampling the encoded signal using the decoding signal, and determining a value of each of a plurality of decoded bits represented by the encoded signal based on the sampling. Also, a method of operating a shift register wherein the shift register has an initialization state wherein a first binary symbol is stored in a first position and a second binary symbol different than the first binary symbol is stored in each of one or more intermediate positions and a last position. The method includes determining that the shift register is full responsive to detecting that the first binary symbol has been stored in either one of the intermediate positions or the last position. | 08-08-2013 |
20130197893 | METHODS FOR MODELING HEPATIC INFLAMMATION - Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, infection, damage, fibrosis/cirrhosis, and cancer. | 08-01-2013 |
20130197468 | Device for Intramyocardial Delivery - Methods and apparatuses for delivery of biologically active material and/or sensors to a target organ or system. The apparatuses allow for specific, controlled delivery of the biologically active material and targeted placement of sensors. The apparatuses may be fabricated from cellular and/or acellular biological active components to promote integration of sensors into tissue and achieve appropriate release of biologically active molecules. The apparatuses may be fabricated from plasma-containing materials or other biopolymers such that the apparatus will resorbed into the tissue following insertion. The biologically active cellular or acellular component may be incorporated into that material may then serve as the source of the therapeutic biologically active component. The apparatus may take the form of a screw, though numerous shapes arc contemplated. The delivery methods and apparatuses of the present invention may be employed in a wide variety of physiological and medical situations, with cardiac implementations being particularly appropriate. | 08-01-2013 |
20130197418 | CATHETER - In one aspect, the invention provides a device comprising a catheter. In another aspect, the invention provides a method of removing an agent from blood. | 08-01-2013 |
20130190687 | IMPLANTABLE MEDICAL DEVICES HAVING DOUBLE WALLED MICROSPHERES - An implantable medical device including at least one double-walled microsphere containing an active agent, and a biodegradable polymer layer containing the at least one double-walled microsphere. | 07-25-2013 |
20130183707 | STEM CELL BIOINFORMATICS - Ex vivo cell culture, especially the culture of stem cells, is a valuable and widely used technique. The appearance of unlabeled cultured cells contains significant information about the cell's identity, including its differentiation status and lineage. However, mere visual inspection of cells is a subjective process subject to inconsistencies between microscopists. This disclosure provides methods of quantifying cells' appearance, validating identity with known biomarkers, allowing automated classification of cells as well as automated segmentation and delineation of the borders of a cell colony. Also provided are systems and methods for comparing and standardizing cells cultured by different scientists using different cell culture methods. | 07-18-2013 |
20130181048 | METHOD AND APPARATUS FOR STORING AND TRACKING INFORMATION RELATING TO A MEDICAL IMPLANT DEVICE - A system for storing information relating to a medical implant device implanted in a patient includes a credit card sized card device structured to be carried by the patient external to the patient's body. The card device includes a wireless transponder device securely storing information relating to at least one of the medical implant and the patient. The system also includes a reader device structured to selectively and securely read the information from the wireless transponder device. In one implementation, the reader device is able to selectively and securely read the information from the wireless transponder device using a direct electrical connection (e.g., using transcutaneous contact) without an air interface. | 07-18-2013 |
20130178788 | ELECTROOSMOTIC CONVECTION-ENHANCED DELIVERY SYSTEM - Apparatuses and methods for electrokinetic transport of fluids to patients. Drug-containing solutions may be placed in vial-like reservoir, which is connected to an apparatus such as a traditional catheter or other device capable of holding a drug-containing solution. Instead of a vial-like reservoir, a doped infusion pad or a gel may be used as a source of the drug-containing solution. The reservoir and apparatus may thus be the same component. The methods and apparatuses disclosed herein may also be used to transport fluid alone to achieve a clinical effect. The apparatus is placed at the point of drug delivery. The counter-electrode may be placed in or on a patient. Current is passed from the reservoir to the counter-electrode. Through electrokinetic transport, drug-containing solution is delivered along a current path from the drug source to the counter-electrode. A hollow fiber catheter for use in electrokinetic transport is also disclosed. | 07-11-2013 |
20130178158 | WIRELESS SYSTEMS HAVING MULTIPLE ELECTRONIC DEVICES AND EMPLOYING SIMPLIFIED FABRICATION AND MATCHING, AND ASSOCIATED METHODS - A means and method to connect multiple IC chips to a single apparatus where the IC chips may function as a passive system or network in space. The collection of antennae and coupled near field devices form a pool of energy in which multiple devices may be introduced so as to provide a pool of energy and/or to function as a network or networks of devices including IC chips. | 07-11-2013 |
20130172388 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES - Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: | 07-04-2013 |
20130165877 | AUGMENTED CHEST TUBE DRAINAGE SYSTEM AND METHOD WITH VOLUME SENSING, AUTOMATED ALERTS AND MESSAGING CAPABILITY - Systems and methods that can augment conventional chest tube drainage canisters are discussed. One such system can monitor a chest tube drainage canister that collects fluid and includes a volume sensor that can determine a volume of the fluid. Such a system can also include a control component that calculates a flow rate of the fluid. The control component can compares the volume and the flow rate with one or more predetermined conditions, and the control component provides at least one notification to a healthcare professional when at least one of the predetermined conditions are met. Additionally, a user interface can be provided for monitoring fluid volume and flow rate, entering alerts capable of defining conditions for notification of healthcare professionals, and entering contact information for automatic notification of healthcare professionals via email or text message in connection with the alerts. | 06-27-2013 |
20130158662 | Muscle Derived Cells For The Treatment Of Gastro-Esophageal Pathologies And Methods Of Making And Using The Same - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux. | 06-20-2013 |